idea-005 · viability deck
Every slide states a condition that would have to be true, then reports where it stands using the candidate file's own claim and its own confidence tag. A deck never upgrades a tag, invents a number, or recommends anything, and there is no ask slide.
The chair: the investor, and the operator who would have to commission a multi-site validation study before there is any revenue at all.
How to read this: every slide is a condition, not a conclusion. A bracketed claim reference points into knowledge-base/candidates/idea-005.md — the number is the claim's position in its ## Claims list, the tag is copied from it and never adjusted here. A [no claim] marker means nothing in the file speaks to the condition at all. No number appears here that is not in a claim, and there is no ask slide. See docs/deck-spec.md.
What changed since the 2026-08-24 build — this deck's central statement is now wrong and has been replaced. That build said this candidate "has no verified claims at all". It now has seven [claim 26: verified] through [claim 32: verified]. None of them is commercial; all of them are regulatory or clinical. What that does to the investment case is on slide 4 and slide
Would have to be true: A commercial plan or a state Medicaid programme would have to pay for an unattended sleep study in a child — which, on this file's own account, is exactly what they currently do not do.
Where it stands: The coverage exclusion is asserted and unchecked [claim 8: unconfirmed], and the candidate's own conditional isolates the question that decides everything: how the exclusion is worded [claim 9: unconfirmed]. Nothing in the seven new verified claims touches payer policy — they are clinical and regulatory, and payer behaviour has no connector in this repo. One of them does bear on the argument a payer would be shown: a professional society position recommending against the modality in this population [claim 28: verified] is the sort of document a medical-policy committee cites when writing an exclusion.
What would settle it: Three named commercial medical policies for home sleep testing and two state Medicaid policies, read by hand — and specifically read for how the exclusion is worded, since the candidate's own conditional turns on that single distinction. Read them also for whether they cite [claim 28: verified].
If it's false: In the direction that matters — if the exclusion is written as a device restriction, clearance unlocks payment and the candidate's plan works. If it is written as an age restriction, the product is a policy campaign with a device attached, and the go-to-market is lobbying rather than selling.
Would have to be true: A code, a payment, and a coverage policy — and here the third is the one everything turns on.
Where it stands:
unconfirmed and permanently so — CPT is AMA-licensed and this repo cannot reproduce
the descriptors under any circumstance [claim 1: unconfirmed], [claim 2: unconfirmed].
What would settle it: A licensed AMA source for the descriptors — a purchase, not a lookup; the CMS caches for benchmark rates, noting that Medicare will not show this population; and the payer policies themselves for the coverage question that decides it.
If it's false: Factor 2 has nothing under it, and the reimbursement pathway is a campaign of unknown length rather than a code to bill.
Would have to be true: Enough pediatric referrals, at enough revenue per study, with a reachable share.
Where it stands: All three components are unbacked [claim 5: unconfirmed], [claim 6: unconfirmed], [claim 7: unconfirmed]. The population's upper bound is now verified and it is wide rather than precise: pediatric OSAS prevalence ranged from 0% to 5.7% across the literature the 2012 AAP technical report reviewed [claim 29: verified] — a range whose top is more than five times its floor, which is a real constraint on any TAM built from prevalence rather than from claims.
What would settle it: A commercial and Medicaid claims extract for pediatric PSG volume — the only source that sees this population; a sleep-lab price benchmark for the per-study figure.
If it's false: TAM is a hard kill condition. Here it is unresolved because the connectors point at Medicare, which is the wrong programme — a tooling gap, not a market finding, and Stage 5 correctly declines to fire on it.
Would have to be true: A prospective multi-site validation study with concurrent in-lab PSG in several hundred children would have to be affordable — because nothing ships without it.
Where it stands: The cost estimate is unbenchmarked and is the largest number in the file [claim 12: unconfirmed]. What the new verified evidence changes is what that study has to achieve. The last build framed it as buying a label. It now has to clear a higher bar: the AASM's 2017 position recommends against HSAT for pediatric OSA diagnosis on grounds that name this device's architecture [claim 28: verified], and the existing simultaneous concordance literature is three studies deep [claim 30: verified]. A study large enough to move a society position is a different object from a study large enough to support a 510(k). Against that, the regulatory half got cheaper: the pediatric-permitting pathway is demonstrably walkable [claim 3: refuted], [claim 26: verified], so the clearance risk the frontmatter worried about is lower than assumed.
What would settle it: The registered pediatric HSAT trials for a real cost and enrolment benchmark [claim 4: unconfirmed]; a pre-submission meeting with FDA for the route; and the payer policy wording, before the study is commissioned rather than after.
If it's false: Both the number and its ordering are wrong — a mid-single-digit-million study spent to unlock a payment that was never gated on clearance.
Would have to be true: The pediatric validation dataset and the cleared pediatric indication would have to be defensible — and the refutation on this file damages both.
Where it stands: The moat rests on the validation dataset and the pediatric scoring algorithm [claim 10: unconfirmed]. The cleared-indication half of it is gone: pediatric use is already permitted in marketed devices, from a roster of 38 clearances [claim 3: refuted]. That leaves the dataset, which an incumbent with an existing cleared platform can replicate at lower marginal cost [claim 13: unconfirmed]. FTO was never asked [claim 25: unconfirmed].
What would settle it: The full indications-for-use text of every MNR clearance permitting pediatric use — the file has already pulled the roster; a patent landscape on pediatric scoring algorithms.
If it's false: The company's asset is a study that an incumbent can replicate, and the study is also the company's entire capital requirement [claim 12: unconfirmed].
Would have to be true: The pediatric indication would have to be genuinely open — and the file's own verification says it is not as open as the candidate assumed.
Where it stands: 38 MNR clearances over 2020-2026, at least one stating verbatim that "both pediatric and adult patients may be tested" [claim 3: refuted], with the classification record verified [claim 26: verified]. The adult HSAT incumbents hold cleared platforms one validation study away from this indication [claim 13: unconfirmed]. One quality datum is verified: a terminated recall against a marketed MNR recorder [claim 27: verified] — a single event, not a pattern.
What would settle it: The sponsor fields on the registered pediatric HSAT trials [claim 4: unconfirmed] — an incumbent already running a pediatric validation study is the most decisive competitive fact available and is one cheap lookup away.
If it's false: Read it inverted — the risk is that the field is already legally open and nobody has commercialised it, which is information about demand, not about permission. The seven verified claims now offer a candidate explanation for that silence [claim 28: verified].
Would have to be true: Reading five payer policies and one trial registry field would have to reorder the entire investment case before any study is commissioned.
Where it stands: Unchanged and unspent. The research lane's work went into clinical evidence, which is why this candidate now has seven verified claims and still has zero commercial evidence of any kind. Three commercial policies, two Medicaid policies, and the sponsor field on two ClinicalTrials.gov records remain the shortest high-value work order in this repo.
What would settle it: Those five policies and that one registry field. Add one more now that it is cheap: read the three simultaneous studies inside [claim 30: verified], because they determine whether the study on the critical path is a replication or a first.
If it's false: Nothing here is false — this is a work order, and it is still the shortest one in this repo.
Every condition above with nothing verified behind it.
The asymmetry to carry to Stage 6: all seven verified claims are clinical or regulatory, and not one is commercial. This candidate is the best-evidenced in the portfolio on whether the device could work and among the least evidenced on whether anyone would pay for it — and the payer question is the one its own conditional says decides the business.
If only one thing from this chair could be checked: how the pediatric home-sleep-testing exclusion is worded in real payer policies — as an age restriction or as a device-clearance restriction [claim 9: unconfirmed].
The candidate itself isolates this and it is the correct isolation. If the exclusion is a device restriction, the validation study buys coverage and the business is what it says it is. If it is an age restriction, the study buys a label and nothing else, and revenue waits on a policy campaign of unknown duration — after mid-single-digit millions has already been spent [claim 12: unconfirmed].
Two things now make the question urgent rather than academic, and they compound. Clearance permitting pediatric testing already exists and the practice has not moved [claim 3: refuted] — so clearance was never the binding constraint. And there is now a verified professional-society position recommending against the modality in children, on grounds aimed at this device's architecture [claim 28: verified] — which is exactly the kind of document a payer's medical-policy committee cites when it writes an exclusion, and which would make an age-worded exclusion the more likely of the two possibilities rather than the coin flip the last build treated it as.
Reading the policies is still the cheapest act available on this candidate, and it is now worth more than it was.
Naming it is not a recommendation, a gate, or a kill.